Eli Lilly Resubmits BLA for Lebrikizumab for the Treatment of Moderate to Severe AD
A decision from the FDA is expected in the second half of 2024.
A decision from the FDA is expected in the second half of 2024.
The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.
The Adbry 300 mg/2 mL autoinjector reduces the number of self injections required for patients, who currently have a 150mg/1mL pre-filled syringe available.
This case-control study examines the association of precocious puberty with hidradenitis suppurativa among US children and adolescents.
Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.
Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.
Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.
Saturday, October 26, 2024 6:15 am – 7:15 am ET Sheraton Boston Hotel | Boston, Massachusetts In-Person Food allergies affect both children and adults. They…
Five experts delve into the multifaceted aspects of pediatric atopic dermatitis care including demographic variances to long-term safety and efficacy, comparative analyses, key takeaways from…
Hilary Baldwin, MD, emphasized involving patients in the decision-making process to create a personalized and cost-effective plan.
One of the joys of dermatology is that there is rarely a dull moment.